Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness.

Ter Avest, Mendy; Langemeijer, Saskia M C; Blijlevens, Nicole M A; van de Kar, Nicole C A J; Ter Heine, Rob

Ter Avest, Mendy; Langemeijer, Saskia M C; Blijlevens, Nicole M A; van de Kar, Nicole C A J; Ter Heine, Rob.

Afiliação

Ter Avest M; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Langemeijer SMC; Department of Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Blijlevens NMA; Department of Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
van de Kar NCAJ; Deparment of Paediatric Nephrology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Ter Heine R; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.

Br J Clin Pharmacol ; 89(3): 1211-1215, 2023 03.

Article em En | MEDLINE | ID: mdl-36394176

Assuntos

Hemoglobinúria Paroxística; Humanos; Hemoglobinúria Paroxística/tratamento farmacológico; Anticorpos Monoclonais Humanizados/uso terapêutico; Inativadores do Complemento/uso terapêutico

Palavras-chave

paroxysmal nocturnal haemoglobinuria; pharmacodynamics; pharmacokinetics; ravulizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemoglobinúria Paroxística Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google